



**Comparative study between traditional
increasing heparin dose versus the use of fresh
frozen plasma in management of heparin
resistance
Thesis**

*Submitted for Partial Fulfillment of M.D. Degree
In Anesthesiology*

Presented by

Ahmed Mohamed Shehata Mohamed
*M.B.B.Ch, M.Sc., Anesthesiology Faculty of Medicine, Ain Shams
University*

Supervised by

Prof. Dr. Bahaa Eldin Ewees Hassan
*Professor of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Prof.Dr. Ahmed Nagah El-Shaer

*Professor of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Dr. Hany Victor Zaki

*Lecturer of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Dr. Marwa Ahmed Khairy

*Lecturer of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2015**

Acknowledgments

First of all, all gratitude is to **ALLAH** for blessing this work until it has reached its end, as a part of his generous help throughout my life.

I would like to express my deepest gratitude to **Prof. Dr. Bahaa Eldin Ewees Hassan** Professor of Anesthesia and intensive Care, Faculty of Medicine - Ain Shams University, for the great support and encouragement he gave me throughout the whole work. It is an honor to work under his guidance and supervision.

I also wish to thank **Prof. Dr. Ahmed Nagah El-Shaer** professor of Anesthesia and intensive care, Faculty of Medicine - Ain Shams University, for his kind guidance and revision for the whole work.


This work would have never been completed without the great help, close supervision offered by **Dr. Hany Victor Zak** Lecturer of Anesthesia and intensive Care, Faculty of Medicine - Ain Shams University.

I am deeply indebted to **Dr. Marwa Ahmed Khairy** Lecturer of Anesthesia and intensive Care, Faculty of Medicine - Ain Shams University, for her close observation and faithful advices.

Ahmed Shehata

Table of Contents

Introduction.....	1
Review of Literature	
Heparin Pharmacology.....	4
Heparin Monitoring	23
Heparin Resistance.....	32
Materials & Methods	38
Results	43
Discussion	71
Summary	80
References	81




List of Abbreviation

List of abbreviations

ABW	Adjusted Body Weight
ACT	Activated Clotting Time
aPTT	activated partial thromboplastin times
AT	antithrombin
DTI	Direct Thrombin Inhibitor
DVT	Deep venous thrombosis
H-AT	heparin-antithrombin
HIT	Heparin Induced Thrombocytopenia
HIV	Human Immunodeficiency Virus
IBW	Ideal Body Weight
ICU	Intensive Care Unit
ISMP	Institute for Safe Medication Practices
IU	International unit
IV	Intra venous
FFP	Fresh Frozen Plasma

fVa	Activated factor V
fXa	activated factor X
h	hour
Kg	Kilogram
mL	Milli – liter
PF4	Platelets factor four
SD	Standard Deviation
TBW	Total Body Weight
TFPI	tissue factor pathway inhibitor
U	unit
UFH	Unfractionated heparin



List of Tables

List of tables

Number	<i>Titles</i>	Page
Table 1	Weight-based dosing protocol	21
Table 2	Weight based nomogram for continuous intra-vascular UFH infusion using aPTT	38
Table 3	personal data in the two groups	42
Table 4	Diagnosis on admission in the two groups.	43
Table 5	Baseline aPTT and Platelet count in Day 0 in the two groups.	44
Table 6	aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa and Platelet count in Day 1 in the two groups.	47
Table 7	Number (and percentage) of patients who reached therapeutic level as regard aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa in Day 1in the two groups.	50
Table 8	aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa and Platelet count in Day 2in the two groups	51
Table 9	Number (and percentage) of patients who reached therapeutic level as regard aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa in Day 2 in both groups.	54
Table 10	aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa and	55

	Platelets count in Day 3 in both groups.	
Table 11	Number (and percentage) of patients who reached therapeutic level as regard aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa in Day 3 in both groups.	58
Table 12	aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa and Platelets count in Day 4 in the two groups.	59
Table 13	Number (and percentage) of patients who reached therapeutic level as regard aPTT 1, aPTT 2, aPTT 3, aPTT 4, Xa in Day 4 in both groups.	62




List of Figures

List of figures

Number	<i>Titles</i>	Page
Figure 1	Heparin structural variants.	5
Figure 2	A three-dimensional representation of a portion of a heparin chain.	5
Figure 3	Coagulation cascade	7
Figure 4	New Coagulation cascade	9
Figure 5	Mechanism of action of heparin	10
Figure 6	Dose dependent heparin clearance	13
Figure 7	Heparin-induced thrombocytopenia	17
Figure 8	Factor Xa heparin assay	27
Figure 9	Baseline aPTT in Day 0 in the two groups	45
Figure 10	Comparison between the two groups as regards baseline platelets count in day 0.	46
Figure 11	Comparison between the two groups as regards aPTT 1, aPTT 2, aPTT 3 and aPTT 4 in day 1.	48
Figure 12	Comparison between the two groups as regards Xa in day1.	49
Figure 13	Comparison between the two groups as regards platelets count in day 1.	49
Figure 14	Comparison between the two groups as regards aPTT 1, aPTT 2, aPTT 3 and	52

	aPTT 4 in day 2.	
Figure 15	Comparison between the two groups as regards Xa in day2.	53
Figure 16	Comparison between the two groups as regards platelet count in day 2.	53
Figure 17	Comparison between the two groups as regards aPTT 1, aPTT 2, aPTT 3 and aPTT 4 in day 3.	56
Figure 18	Comparison between the two groups as regards Xa in day3.	57
Figure 19	Comparison between the two groups as regards platelets count in day 3.	57
Figure 20	Comparison between the two groups as regards aPTT 1, aPTT 2, aPTT 3 and aPTT 4 in day 4.	60
Figure 21	Comparison between the two groups as regards Xa in day4.	61
Figure 22	Comparison between the two groups as regards platelets count in day 4.	61
Figure 23	Comparison between the two groups as regards percentage of patients reached therapeutic level as measured by aPTT from the start of therapy till the end of the study.	63

<p>Figure 24</p>	<p>Comparison between the two groups as regards percentage of patients reached therapeutic level as measured by anti Xa from the start of therapy till the end of the study.</p>	<p>64</p>
-------------------------	---	------------------



Introduction

. Introduction

Heparin is a sulfated polysaccharide with a molecular weight range of 3000 to 30 000 Da (mean, 15 000 Da). It produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism **(Bentolila et al., 2008)**.

Traditionally, unfractionated heparin has been indicated for the treatment or prevention of spontaneous or iatrogenic (medical procedure-induced) venous or arterial thromboembolism (clotting). Heparin therapy has been demonstrated to be effective in reducing morbidity and mortality associated with established thromboembolism (eg, deep venous thrombosis, pulmonary embolism) and in reducing the risk of thrombus formation (eg, myocardial infarction, unstable angina, coronary angioplasty) **(Segal, 2007)**.

Heparin is given parentally because it is not absorbed from the gut, due to its high negative charge and large size. Heparin can be injected intravenously or subcutaneously. Intramuscular injections are avoided for